ALMS (23) OBX (39) CRVS (31) JBIO (36) ⌘ Pro Terminal →

Inventiva S.A. American Depository Shares (IVA) — RQD Stock Rating Cockpit

$3.73 +0.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Inventiva S.A. American Depository Shares (IVA) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $881.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IVA)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

53.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE20% OF RANGE

L: $3$3.73H: $7

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D+RQD 21 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on IVA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (60)

21/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like IVA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (IVA Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IVA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.29%📐 HORIZONTAL RANGE

2026-10-30O $3.69H $3.76L $3.59C $3.73VOL 1.73M

RES: $5.45SUP: $2.31SMA50: $3.82SMA200: $4.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IVA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IVA Butterfly Map → + Track IVA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IVA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IVA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IVA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IVA)

Health Care Rank #188 of 1016 ⚔️ ALMS vs IVA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IVA vs. ALMS, OBX, CRVS, JBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Inventiva S.A. American Depository Shares (IVA) ranks #188 by composite RQD confidence (61/100, grade C-) and #379 by equity capitalization ($881.3M). Within this direct 5-issuer industry benchmark cohort, IVA leads on earnings valuation at N/A trailing P/E, while ALMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IVA ACTIVE Inventiva S.A. American Depository Shares	C-	61/100	—	—	—	+0.54%	$881.3M	Benchmark Subject
ALMS Alumis Inc.	E	23/100	—	—	-35.0%	-3.37%	$891.8M	/alms-vs-iva →
OBX Obsidian Therapeutics Inc.	D-	39/100	—	—	-35.0%	-0.48%	$896.9M	/obx-vs-iva →
CRVS Corvus Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-2.76%	$860.6M	/crvs-vs-iva →
JBIO Jade Biosciences Inc.	D-	36/100	—	—	-35.0%	-2.40%	$905.6M	/jbio-vs-iva →

2. IVA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Inventiva S.A. American Depository Shares (IVA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $881.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IVA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IVA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Inventiva S.A. American Depository Shares (NASDAQ: IVA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $3.73 (+0.54% 1D, market cap $881.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IVA ranks #188 in composite RQD confidence.

How does IVA compare to ALMS and OBX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IVA carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALMS (Alumis Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $891.8M) and OBX (Obsidian Therapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $896.9M). Among the 5-stock peer group, IVA leads on earnings multiple (N/A) while ALMS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IVA?

For Inventiva S.A. American Depository Shares (IVA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #188 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IVA trading relative to its 50-day, 200-day, and 52-week technical levels?

IVA last traded at $3.73 (+0.54% on volume of 1,435,337 shares), positioning the stock -2.36% below its 50-day simple moving average ($3.82) and -23.57% below its 200-day simple moving average ($4.88). Across its 52-week range of $2.82 to $7.29, IVA sits at the 20.4% percentile with a 14-day RSI of 53.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.26 to $4.20).

IVA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IVA stock right now?

Inventiva S.A. American Depository Shares (IVA) currently earns a Roarable Rating of C- (Hold — HOLD) with 61/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is IVA's 12-month price target and RQD AI Jury consensus?

IVA's 12-month base price target is $3.78 (range $2.95 to $7.65), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IVA RQD Cockpit IVA 12M Forecast IVA Earnings & Move IVA Dividends & DRIP IVA Insiders & 13F IVA Whale Options IVA Profit Sankey IVA News & Why